My watch list
my.bionity.com  
Login  

Acinetobacter baumannii



Acinetobacter baumannii

Acinetobacter baumannii
Scientific classification
Kingdom: Bacteria
Phylum: Proteobacteria
Class: Gamma Proteobacteria
Order: Pseudomonadales
Family: Moraxellaceae
Genus: Acinetobacter
Brisou & Prévot 1954
Species: A. baumannii

Acinetobacter baumannii is a species of pathogenic bacteria which forms opportunistic infections.[1] There have been many reports of drug-resistant A. baumannii infections among American soldiers wounded in Iraq.[2] These 'multi-drug resistant Acinetobacter baumannii' are often referred to as MDRAB.

Contents

Biology

See also the main article on the Acinetobacter genus

Acinetobacter baumannii is the most relevant human pathogen within the Acinetobacter genus. Most A. baumannii isolates are multiresistant, containing in their genome small, isolated islands of alien (meaning transmitted genetically from other organisms) DNA and other cytological and genetic material; this has led to more virulence.[1]

Acinetobacter have no flagellum; the name is Latin for 'motionless'.[3]

Transmission and Prevalence

Acinetobacter enters into the body through open wounds, catheters, and breathing tubes. It usually infects those with compromised immune systems, such as the wounded, the elderly, children or those with immune diseases. Colonisation poses no threat to people who aren't already ill, but colonized health care workers and hospital visitors can carry the bacteria into neighboring wards and other medical facilities.[4] The number of nosocomial infections (hospital-acquired infections) caused by A. baumannii has increased in recent years.[5]

The first military outbreaks of severe A. Baumannii infections occurred in April, 2003 in American soldiers returning from Iraq. Early reports attributed the infections to the Iraqi soil. Later testing demonstrated widespread contamination of field hospitals as the most plausible vector.[6]

Virulence and Pathogenicity

This opportunistic pathogen causes a wide variety of serious infections in humans, mostly in compromised patients. Recently, A. baumannii has emerged as an important pathogen among wounded soldiers, threatening civilian and military patients.

Nosocomial A. baumannii bacteremia may cause severe clinical disease that is associated with a high mortality rate of up to 75%.[7] This opportunistic pathogen expresses a myriad of factors that could play a role in human pathogenesis. Among these factors are the attachment to and persistence on solid surfaces, the acquisition of essential nutrients such as iron, the adhesion to epithelial cells and their subsequent killing by apoptosis, and the production and/or secretion of enzymes and toxic products that damage host tissues. However, very little is known about the molecular nature of most of these processes and factors and almost nothing has been shown with regard to their role in bacterial virulence and the pathogenesis of serious infectious diseases. Fortunately, some of these gaps can now be filled by testing appropriate isogenic derivatives in relevant animal models that mimic the infections in humans, particularly the outcome of deadly pneumonia. Such an approach should provide new and relevant information on the virulence traits of this normally underestimated bacterial human pathogen.[1]

Control and Treatment of Infections

Multi-resistant A. baumannii infections are currently treated with imipenem and an older class of drugs known as polymyxins. These, along with stricter infection-control measures, such as monitored hand washing, have lowered infection rates in some military hospitals.[6]

MDRAB infections are difficult and costly to treat. A study at a public teaching hospital found that the mean total hospital cost of patients who acquired MDRAB was $98,575 higher than that of control patients who had identical burn severity of illness indices.[8]

References

  1. ^ a b c Gerischer U (editor). (2009). Acinetobacter Molecular Biology, 1st ed., Caister Academic Press. ISBN 978-1-904455-20-2 . 
  2. ^ Acinetobacter baumannii in Iraq. Retrieved on 2007-02-15.
  3. ^ Asif Zia (2004-04-19). Infectious Disease Case Conference. Wake Forest University. Retrieved on 2007-10-03.
  4. ^ Steve Silberman. "The Invisible Enemy", Wired. Retrieved on 2007-02-15. 
  5. ^ The Coalition of the Contaminated. Mapping Acinetobacter baumannii from Iraq to Civilian Hospitals. Retrieved on 2007-10-03.
  6. ^ a b Jia-Rui Chong. "The path of war sets doctors on the warpath of disease", Napa Valley Register, 2007-10-01. Retrieved on 2007-10-03. 
  7. ^ Cisneros J, Reyes M, Pachón J, Becerril B, Caballero F, García-Garmendía J, Ortiz C, Cobacho A (1996). "Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features". Clin Infect Dis 22 (6): 1026-32. PMID 8783704. Retrieved on 2007-02-15.
  8. ^ Wilson, Stephen (October 2004). "Direct costs of multidrug-resistant Acinetobacter baumannii in the burn unit of a public teaching hospital." 32 (6): 42-344. Retrieved on 2007-10-03.
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Acinetobacter_baumannii". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE